IPO registrations (S-1, F-1) · Registrants
Solid Biosciences Inc.
- SEC CIK
- 1707502 · filings on EDGAR ↗
- Name on the registration
- Solid Biosciences, LLC
- Former names
- Solid Biosciences, LLC (2017–2018)
- Registration
- Form S-1, first filed 2017-12-29, last 2018-01-25; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2018-01-29; declared effective 2018-01-25
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 500 RUTHERFORD AVENUE, 3RD FLOOR, Charlestown, MA 02129
- EIN
- 90-0943402
- Ticker
- SLDB (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Solid Biosciences Inc. on the corporate pages
Offering terms
- Proposed price range
- $18.00–$19.00 per share (S-1/A filed 2018-01-25)
- Final price
- $16.00 per share, below the range (424B4 filed 2018-01-29, an initial public offering)
- Shares sold
- 7,812,500
- Gross proceeds
- $125,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SLDB
- Lead underwriters
- J.P. Morgan; Goldman Sachs; Leerink Partners
- Syndicate
- Nomura; Chardan
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: SOLID BIOSCIENCES INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: SOLID BIOSCIENCES INC. Fuzzy (name and state)
- Form 5500 plan sponsor: SOLID BIOSCIENCES INC EXACT (EIN (EXACT))
- Form D issuer: Solid Biosciences Inc. EXACT (CIK (EXACT))
- SEC filer: Solid Biosciences Inc. EXACT (CIK (EXACT))
- Person page: Ian F Smith Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-12-29 | S-1 | S-1 (registration) | Solid Biosciences, LLC | 0001193125-17-383428 ↗ |
| 2018-01-16 | S-1/A | S-1/A (amendment) | Solid Biosciences, LLC | 0001193125-18-010563 ↗ |
| 2018-01-24 | S-1/A | S-1/A (amendment) | Solid Biosciences, LLC | 0001193125-18-017927 ↗ |
| 2018-01-25 | S-1/A | S-1/A (amendment) | Solid Biosciences, LLC | 0001193125-18-018981 ↗ |
| 2018-01-25 | S-1MEF | S-1MEF (added securities) | Solid Biosciences, LLC | 0001193125-18-020181 ↗ |
| 2018-01-25 | EFFECT | EFFECT (declared effective) | Solid Biosciences, LLC | 9999999995-18-000219 ↗ |
| 2018-01-29 | 424B4 | 424B4 (final prospectus) | Solid Biosciences Inc. | 0001193125-18-023595 ↗ |
| 2019-03-19 | EFFECT | EFFECT (declared effective) | Solid Biosciences Inc. | 9999999995-19-000469 ↗ |
| 2019-10-25 | EFFECT | EFFECT (declared effective) | Solid Biosciences Inc. | 9999999995-19-002396 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-01-25 | S-1/A | registration statement | $18.00–$19.00 | $18.50 | 7,000,000 | $129,500,000 | Nasdaq SLDB | 5 | primary document; range, price sentence, shares headline, proceeds computed, cover names 5 | document ↗ |
| 2018-01-29 | 424B4 | final prospectus | $16.00 | 7,812,500 | $125,000,000 | Nasdaq SLDB | 5 | primary document; price sentence, shares headline, proceeds table, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Amorrortu Pedro Alvaro | Officer | Chief Operating Officer | 8 | 2018–2019 | |
| Arnold Matthew Bennett | Director; Director,TenPercentOwner | 10 | 2018–2020 | ||
| EDELMAN JOSEPH | Director,TenPercentOwner; TenPercentOwner | 18 | 2018–2026 | ||
| Ganot Ilan | Director; Director,Officer | CEO & President; Chief Executive Officer | 45 | 2018–2026 | |
| Hayeem Gilad David | Director,Officer,TenPercentOwner; TenPercentOwner | President | 2 | 2018 | |
| Huffines Robert Luther | Director | 8 | 2018–2022 | ||
| JPMC Strategic Investments II Corp | Other; TenPercentOwner | 2 | 2018 | ||
| JPMORGAN CHASE & CO | Other; TenPercentOwner | 2 | 2018 | ||
| Koppel Adam | Director; Director,TenPercentOwner | 15 | 2018–2024 | ||
| Morris Carl Ashley | Officer | Chief Scientific Officer | 16 | 2018–2023 | |
| PERCEPTIVE ADVISORS LLC | Director,TenPercentOwner | 18 | 2018–2026 | ||
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director,TenPercentOwner; TenPercentOwner | 14 | 2018–2026 | ||
| Quiroz Jorge Armando | Officer | Chief Medical Officer | 5 | 2018–2019 | |
| Schneider Joel Solomon Zev | Officer | Chief Operating Officer; Chief Technology Officer; See Remarks | 15 | 2018–2022 | |
| Shah Rajeev M. | Director; Director,TenPercentOwner; TenPercentOwner | 18 | 2018–2026 | ||
| Stone Adam Leo | Director | 11 | 2018–2026 | ||
| Sullivan Lynne Marie | Director | 12 | 2018–2026 | ||
| Zarur Juan Andrey | Director | 8 | 2018–2020 | ||
| Ziolkowski Jennifer Lynn | Officer | CFO, Treasurer & Asst. Secy; Chief Financial Officer; See Remarks | 8 | 2018–2021 | |
| Freed Martin I | Director | 14 | 2018–2026 | ||
| Nagendran Sukumar | Director | 13 | 2018–2026 | ||
| HERSCHA LYNETTE | Officer | Chief Legal Officer; See Remark; See Remarks | 6 | 2019–2020 | |
| Boxer Asset Management Inc. | TenPercentOwner | 1 | 2019 | ||
| Boxer Capital, LLC | TenPercentOwner | 2 | 2019 | ||
| Braslyn Ltd. | TenPercentOwner | 1 | 2019 | ||
| LEWIS JOSEPH | TenPercentOwner | 1 | 2019 | ||
| MVA Investors, LLC | TenPercentOwner | 1 | 2019 | ||
| SMITH IAN F | Director | 31 | 2020–2026 | person page Fuzzy | |
| Ultragenyx Pharmaceutical Inc. | TenPercentOwner | 1 | 2020 | ||
| Kolchinsky Peter | Director,TenPercentOwner; TenPercentOwner | 10 | 2020–2026 | ||
| RA Capital Healthcare Fund LP | Director,TenPercentOwner; TenPercentOwner | 10 | 2020–2026 | ||
| RA CAPITAL MANAGEMENT, L.P. | Director,TenPercentOwner; TenPercentOwner | 10 | 2020–2026 | ||
| DiPalma Stephen J. | Officer | Interim CFO | 1 | 2021 | |
| Brennan Erin Powers | Officer | Chief Legal Officer, Secretary | 5 | 2021–2022 | |
| Kahn Clare | Director | 10 | 2021–2026 | ||
| Keresty Georgia | Director | 8 | 2021–2026 | ||
| Bain Capital Life Sciences Fund II, L.P. | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| Bain Capital Life Sciences Investors II, LLC | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| Bain Capital Life Sciences Investors, LLC | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| Bain Capital Life Sciences Partners, LP | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| BCIP Life Sciences Associates, LP | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| BCLS II Investco (GP), LLC | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| BCLS II Investco, LP | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| BCLS SB Investco, LP | Director,TenPercentOwner; TenPercentOwner | 3 | 2022–2025 | ||
| Cumbo Alexander | Director,Officer | President and CEO | 13 | 2022–2026 | |
| Hanrahan Jessie | Officer | Chief Regulatory Officer | 13 | 2022–2026 | |
| Herzich Paul | Officer | Chief Technology Officer | 13 | 2022–2026 | |
| Howton David T | Officer | Chief Operating Officer; See Remarks | 13 | 2022–2026 | |
| Marlowe Jennifer | Officer | CSO; CSO, FA & Cardiac | 4 | 2022–2024 | |
| RA Capital Nexus Fund, L.P. | Director,TenPercentOwner | 4 | 2022–2024 | ||
| Perceptive Venture Advisors, LLC | Director,TenPercentOwner | 1 | 2022 | ||
| Perceptive Xontogeny Venture Fund, LP | Director,TenPercentOwner | 3 | 2022–2025 | ||
| Tan Kevin | Officer | CFO & Treasurer | 13 | 2023–2026 | |
| Brooks Gabriel | Officer | Chief Medical Officer | 12 | 2023–2026 | |
| BCLS II Equity Opportunities GP, LLC | Director,TenPercentOwner; TenPercentOwner | 2 | 2024–2025 | ||
| BCLS II Equity Opportunities, LP | Director,TenPercentOwner; TenPercentOwner | 2 | 2024–2025 | ||
| Adage Capital Management, L.P. | TenPercentOwner | 2 | 2025 | ||
| Atchinson Robert | TenPercentOwner | 2 | 2025 | ||
| Gross Phillip | TenPercentOwner | 2 | 2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2022-12-09 | Solid Biosciences Inc. | Pharmaceuticals | $9,200,000 | $9,200,000 | 13 | 1 |
| 2020-10-26 | Solid Biosciences Inc. | Pharmaceuticals | $39,999,996 | $39,999,996 | 1 | 1 |
| 2019-07-31 | Solid Biosciences Inc. | Pharmaceuticals | $59,977,035 | $59,977,035 | 15 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | SOLID BIOSCIENCES INC. | MA | State business registries | EIN (EXACT, as the state registration reports it) |
| Business registration | SOLID BIOSCIENCES INC. | MA | State business registries | name and state |
| Form D issuer | Solid Biosciences Inc. | MA | Form D private offerings | CIK (EXACT) |
| SEC filer | Solid Biosciences Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Solid Biosciences Inc. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | SOLID BIOSCIENCES INC | EIN (EXACT) | ||
| Person page | Ian F Smith | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.